Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin to Prevent AKI to CKD Transition
NCT05713851Phase 3Recruiting
- Sponsor
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute kidney injury (AKI) comparing Dapaglifozin group with Standard of care (2 arms). Primary endpoint: Mean change in urinary Serpin A3 levels at 18 months. Started Jan 2023; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05713851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05713851.